NCT01095731 is a Phase 2 clinical trial of Tiopronin in Aneurysmal Subarachnoid Hemorrhage, sponsored by E. Sander Connolly.

Who is sponsoring NCT01095731?

NCT01095731 is sponsored by E. Sander Connolly.

What drugs are being tested in NCT01095731?

Interventions in NCT01095731: Tiopronin, Placebo.

What condition does NCT01095731 study?

NCT01095731 studies Aneurysmal Subarachnoid Hemorrhage.

Is NCT01095731 still recruiting?

NCT01095731 is currently completed. Last updated 30 September 2025.

Are results published for NCT01095731?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-09-30 · How we verify

NCT01095731

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study of the Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

Completed Phase 2 Results posted Last updated 30 September 2025

What this trial tests

Phase 2 trial testing Tiopronin in Aneurysmal Subarachnoid Hemorrhage in 60 participants. Completed in 1 July 2013.

Timeline

1 April 2010

Primary endpoint
1 July 2012

1 July 2013

Quick facts

Lead sponsor	E. Sander Connolly
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	1 April 2010
Primary completion	1 July 2012
Estimated completion	1 July 2013
Sites	3 locations across United States

Drugs / interventions tested

Tiopronin — full drug profile →
Placebo

Conditions studied

Aneurysmal Subarachnoid Hemorrhage — all drugs for Aneurysmal Subarachnoid Hemorrhage →

Sponsor

E. Sander Connolly

Who can join

21 and older, any sex, with Aneurysmal Subarachnoid Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cerebrospinal Fluid 3-aminopropanal (CSF-3AP) Levels
Time frame: Day 7
The level of 3-aminopropanal (3-AP) in cerebrospinal fluid (CSF) measured in nmol/mL. CSF samples taken as a standard of care.

Sponsor's own description

The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical trials in cardiac arrest and subarachnoid hemorrhage: lessons from the past and ideas for the future.
Frontera JA. · · 2013 · cited 4× · PMID 23533956 · DOI 10.1155/2013/263974
A phase II randomized controlled trial of tiopronin for aneurysmal subarachnoid hemorrhage.
Ironside N, Christophe B, Bruce S, Carpenter AM, et al · · 2020 · cited 1× · PMID 31299655 · DOI 10.3171/2019.4.jns19478

Verify or expand the search:

Other trials of Tiopronin

Trials testing the same drug.

NCT03663855 — Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria · Phase 2 · completed

Other recruiting trials for Aneurysmal Subarachnoid Hemorrhage

Currently open trials in the same condition.

NCT06863480 — Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events · Phase 1 · recruiting
NCT06409364 — FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage · Phase 2 · recruiting
NCT06494436 — Microvention AnEurysm & STroke Real-life Data cOllection · recruiting
NCT06548477 — Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages · NA · recruiting
NCT06288659 — aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01095731 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by E. Sander Connolly
Last refreshed: 30 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01095731.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing